In this episode, we take a closer look at CLINUVEL’s intention to uplift its American Depositary Receipts (ADRs) from a Level I to a Level II program on Nasdaq. To unpack the technical aspects of this transition, we are joined by our Head of Investor Relations, Mr Malcolm Bull, who discusses the rationale behind the move and how it supports the Company’s ambition to expand its presence in the U.S. market.
- Home
- People
- CLINUVEL news
A Podcast by CLINUVEL: Navigating CLINUVEL’s ADR Uplift — Insight and Rationale
In this episode, we take a closer look at CLINUVEL's intention to uplift its American Depositary Receipts (ADRs) from a Level I to a Level II program on Nasdaq.CLINUVEL newsA Podcast by CLINUVEL: The importance of pharmacovigilance
This episode, we welcome Dr Azza Hamila, CLINUVEL’s Head of Quality and Drug Safety, to discuss the importance of pharmacovigilance—the essential, ongoing system that constantly monitors and evaluates the safety profile of a drug once it is in wider use.CLINUVEL newsA Podcast by CLINUVEL: Building a vitiligo community and finding hope
Tonja Johnson, founder of Beautifully Unblemished, opens up about the emotional turmoil she faced after her diagnosis in 2014 and the quiet epiphany she had: that helping herself meant connecting with others.CLINUVEL newsA Podcast by CLINUVEL: From discovery to regulatory approval — a brief history of afamelanotide (Part 1)
In the first of a two part series, hear directly from Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer, who led the much of the development and regulatory work. He recounts the challenges and triumphs of navigating the process from a promising discovery to a regulatory success for rare disease patients.
- R&D
- CLINUVEL news
A Podcast by CLINUVEL: From discovery to regulatory approval — a brief history of afamelanotide (Part 1)
In the first of a two part series, hear directly from Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer, who led the much of the development and regulatory work. He recounts the challenges and triumphs of navigating the process from a promising discovery to a regulatory success for rare disease patients.CLINUVEL newsA Podcast by CLINUVEL: Behind the label — what is takes to launch safe and effective cosmetics
CLINUVEL’s Regulatory Affairs Manager (Cosmetics), Alice Lynn, is back in this episode to demystify the labels on cosmetic products and explore how brands determine shelf life and efficacy claims. Tune in to learn what it takes to get a safe, effective, and innovative cosmetic from the lab to your vanity table.CLINUVEL newsA Podcast by CLINUVEL: “How did they get it so wrong?” — Unpacking SPF testing
In this podcast episode, CLINUVEL’s Regulatory Affairs Project Manager (Cosmetics), Alice Lynn joined Sarah Mawson to unpack SPF: what is it? How do we test for it? And why some labels may not be what they seem.CLINUVEL newsA Podcast by CLINUVEL: Insights from Dr Emilie Rodenburger on CLINUVEL’s vitiligo program
In this podcast episode, Dr Emilie Rodenburger, Director, Global Clinical Affairs at CLINUVEL, elaborates on the scientific basis for using afamelanotide in vitiligo, and provides insights on key learnings from the program to date.
- Publications
- Publications
The Weekend Effect – A Worrying Truth or Myth?
Reduced staff over the weekends is the norm for many retail shops, but what about in healthcare? A number of reviews have...PublicationsIs skin cancer in your job description?
Those of us working from offices, or our own homes, aren’t expecting danger pay. However, what about those who have jobs that heighten the risk of getting skin...PublicationsTomatoes and carrots… photoprotection from within?
Most of us have been spun a myth that eating our crusts will make our hair shiny, and that we should...PublicationsHas COVID-19 Had an Effect on Sun Protection Behaviours?
Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...
- Finance & investing
- CLINUVEL news
Half Year Results for FY2026 — Investor Webinar
CLINUVEL (ASX:CUV) hosted an investor webinar to review the half year results and operational highlights for the six months ended on 31 December 2025.CLINUVEL newsCLINUVEL 2025 Annual General Meeting – recording
CLINUVEL’s 2025 Annual General Meeting was held on 17 October 2025. Watch the recording from the event.CLINUVEL newsCLINUVEL FY2025 Annual Results – Investor Webinar
CLINUVEL hosted an investor webinar following the release of its FY2025 results on 28 August 2025. Mr Malcolm Bull, Head of Investor Relations and Australia Operations, is joined by Mr Peter Vaughan, Chief Financial Officer, and Dr Philippe Wolgen, Managing Director, to review the results.CLINUVEL newsFirst half results – FY2025
CLINUVEL (ASX:CUV) hosted an investor webinar to review the half year results and operational highlights for the six months ended on 31 December 2024.